NEWRON PHARMACEUTICALS S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.28 CHF | +8.82% |
|
+4.75% | +47.07% |
| Apr. 17 | Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member | CI |
| Mar. 19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 104.4 | 35.36 | 27.92 | 27.93 | 95.03 | 138.9 | - | - |
| Enterprise Value (EV) 1 | 81.95 | 29.79 | 27.92 | 60.17 | 95.03 | 168 | 140.9 | 138.9 |
| P/E ratio | -5.18 x | -1.68 x | -1.86 x | -1.6 x | -5.85 x | 9.56 x | 32 x | 5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 14.8 x | 6.73 x | 4.85 x | 4.58 x | 10.5 x | 3.86 x | 5.35 x | 2.67 x |
| EV / Revenue | 11.6 x | 5.67 x | 4.85 x | 9.87 x | 10.5 x | 4.67 x | 5.43 x | 2.67 x |
| EV / EBITDA | -3.96 x | -1.67 x | -2.3 x | -4.59 x | - | 9.09 x | 15.8 x | 3.75 x |
| EV / FCF | -3.68 x | -1.91 x | - | -5.42 x | - | 4.67 x | 11.7 x | 3.31 x |
| FCF Yield | -27.2% | -52.4% | - | -18.5% | - | 21.4% | 8.52% | 30.2% |
| Price to Book | - | 2.05 x | - | -1.99 x | - | -10.9 x | 20.5 x | - |
| Nbr of stocks (in thousands) | 17,845 | 17,845 | 17,845 | 17,845 | 17,845 | 18,632 | - | - |
| Reference price 2 | 5.848 | 1.982 | 1.565 | 1.565 | 5.325 | 7.455 | 7.455 | 7.455 |
| Announcement Date | 3/5/20 | 3/16/21 | 3/15/22 | 3/14/23 | 3/19/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.038 | 5.258 | 5.762 | 6.094 | 9.057 | 35.98 | 25.95 | 52 |
| EBITDA 1 | -20.69 | -17.85 | -12.15 | -13.1 | - | 18.48 | 8.931 | 37 |
| EBIT 1 | -20.9 | -18.07 | -12.36 | -13.3 | -11.63 | 18.43 | 8.891 | 37 |
| Operating Margin | -296.95% | -343.59% | -214.46% | -218.28% | -128.4% | 51.22% | 34.26% | 71.15% |
| Earnings before Tax (EBT) 1 | -20.16 | -19.62 | -14.88 | -17.47 | - | 14.73 | 5.066 | 35 |
| Net income 1 | -20.21 | -21 | -14.9 | -17.49 | -16.22 | 13.73 | 4.066 | 27 |
| Net margin | -287.11% | -399.35% | -258.61% | -287.05% | -179.13% | 38.17% | 15.67% | 51.92% |
| EPS 2 | -1.130 | -1.180 | -0.8400 | -0.9800 | -0.9100 | 0.7800 | 0.2333 | 1.490 |
| Free Cash Flow 1 | -22.26 | -15.62 | - | -11.11 | - | 36 | 12 | 42 |
| FCF margin | -316.3% | -297.11% | - | -182.31% | - | 100.06% | 46.24% | 80.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 194.83% | 134.36% | 113.51% |
| FCF Conversion (Net income) | - | - | - | - | - | 262.14% | 295.11% | 155.56% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/16/21 | 3/15/22 | 3/14/23 | 3/19/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 32.2 | - | 29.1 | 2 | - |
| Net Cash position 1 | 22.4 | 5.58 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -2.461 x | - | 1.575 x | 0.2239 x | - |
| Free Cash Flow 1 | -22.3 | -15.6 | - | -11.1 | - | 36 | 12 | 42 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | 146% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.9700 | - | -0.7900 | - | -0.6900 | 0.3600 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.05 | 0.03 | 0.02 | - | - | 0.07 | 0.06 | - |
| Capex / Sales | 0.72% | 0.65% | 0.35% | - | - | 0.19% | 0.21% | - |
| Announcement Date | 3/5/20 | 3/16/21 | 3/15/22 | 3/14/23 | 3/19/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.455
EUR
Average target price
13.28
EUR
Spread / Average Target
+78.16%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +47.07% | 148M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- NWRN Stock
- Financials Newron Pharmaceuticals S.p.A.
